Free Trial

OKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% - Time to Sell?

OKYO Pharma logo with Medical background

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares were down 13.7% during trading on Tuesday . The stock traded as low as $2.13 and last traded at $2.21. Approximately 201,376 shares traded hands during trading, an increase of 41% from the average daily volume of 143,002 shares. The stock had previously closed at $2.56.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of OKYO Pharma in a research report on Monday, May 5th.

Check Out Our Latest Analysis on OKYO

OKYO Pharma Stock Up 5.3%

The company has a 50 day moving average price of $1.71 and a 200 day moving average price of $1.35.

Hedge Funds Weigh In On OKYO Pharma

An institutional investor recently bought a new position in OKYO Pharma stock. Dauntless Investment Group LLC bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma makes up approximately 3.0% of Dauntless Investment Group LLC's portfolio, making the stock its 2nd largest position. Dauntless Investment Group LLC owned about 5.88% of OKYO Pharma at the end of the most recent quarter. Institutional investors own 2.97% of the company's stock.

OKYO Pharma Company Profile

(Get Free Report)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

Featured Stories

Should You Invest $1,000 in OKYO Pharma Right Now?

Before you consider OKYO Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.

While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines